Lexicon Pharma (LXRX) Reports In-Line Q1 EPS

Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $1.13 million versus the consensus estimate of $1.37 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• Stay long AI-capex winners into the peak, Stifel says despite bubble fears
• Benchmark Reiterates Hold Rating on Old Dominion Freight Line (ODFL) as 'Quality Largely Priced in'